Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Favrille has entered into definitive agreements with primarily institutional investors to sell up to 7,416,520 shares of its common stock and warrants to purchase up to 4,449,910 shares of its common stock for gross proceeds of approximately $21.1 million, before deducting placement agent fees and estimated offering expenses, in a registered direct offering.
Subscribe to our email newsletter
The investors have agreed to purchase the shares of common stock and warrants to purchase common stock at a negotiated purchase price of $2.845 per unit, each unit consisting of one share and a warrant to purchase 0.6 shares of common stock. The warrants will be exercisable at any time prior to the fifth anniversary of the closing of the transaction. The exercise price of the warrants will be $2.77 per share.
Lazard Capital Markets has served as sole placement agent for the offering. The securities described above are being offered by the company pursuant to a previously filed registration statement, which was declared effective by the Securities and Exchange Commission on July 11, 2006. The transaction is expected to close on or about November 7, 2007, subject to customary closing conditions.